ESMO Congress 2024 Preview for Integrative Care: The Show and After Show

With an abundance of information expected to come out of the European Society of Medical Oncology (ESMO) Congress 2024, providers across the integrative approach to cancer care have the opportunity to learn about the latest developments.

In the next episode of The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec offer a glimpse at some of the most talked about presentations to come, as well as topics that hope to enhance the field even further. Some key highlights include:

Genitourinary Cancer

• NIAGARA (NCT03732677) trial: Thomas Powles, MBBS, MRCP, MD, professor of genitourinary oncology, director, Barts Cancer Centre at St. Bartholomew's Hospital, will present results from the phase 3 NIAGARA trial, designed to evaluate neoadjuvant durvalumab (Imfinzi) plus chemotherapy in patients with muscle-invasive bladder cancer.

Emerging Technologies

• GigaPath: As the use of AI grows in popularity, one of the Presidential Sympoisums will feature information on the application of GigaPath-an open-weight billion-parameter AI foundation model based on a novel vision transformer architecture for cancer mutation prediction and tumor microenviroment analysis, presented by Carlo Bifulco, MD, chief medical officer of Providence Genomics and associate member and medical director of Translational Molecular Pathology, Earle A. Chiles Research Institute.

The co-hosts touch on even more presentations coming out of ESMO Congress 2024, including data from the genitourinary space, overall survival results in triple-negative breast cancer, and a promising study in cervical cancer.

ESMO Congress 2024 isn't just about data, as the duo also offers food recommendations, tourist attractions and fun activities to partake in, as well as interesting facts about Barcelona.

This is just a taste of the wealth of information and inspiration waiting at ESMO Congress 2024. Check back for future meeting previews with The Show and After Show.